经SNA修改的反感性寡核酸:脏向的新途径?
Bernhard Dumoulin1,2,3,4, Ken Yamada5, Katalin Susztak1,2,3,4
1Department of Medicine, Renal Electrolyte and Hypertension Division, University of Pennsylvania, Philadelphia, PA, USA.
Molecular therapy. Nucleic acids
|March 4, 2025
概括
新的醇核酸 (SNA) 修饰的反感性寡核酸 (ASO) 在小鼠脏中显示出有效的基因沉默,并提高了安全性. 这些SNA-ASO为治疗脏疾病提供了有前途的方法.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 反感性寡核酸 (ASO) 是抑制基因表达的治疗剂.
- 由于输送问题和毒性,特别是在重复或高剂量的情况下,ASO的临床使用受到阻碍.
- 针对脏疾病需要有效和安全的治疗策略.
研究的目的:
- 评估修改了醇核酸 (SNA) 的gapmer ASOs的疗效和安全性,针对小鼠中的-葡萄糖共运输体2 (SGLT2).
- 为了比较SNA修改的ASOs与传统的2'-MOE修改的ASOs的性能.
主要方法:
- 开发针对SGLT2的SNA修改的Gapmer ASOs.
- 给小鼠使用SNA-ASOs和2'-MOE修饰的ASOs.
- 在和肝组织中评估基因淘汰,疗效和毒性.
主要成果:
- 经过SNA修改的ASO在小鼠脏中证明了剂量依赖的SGLT2敲击.
- 这些新型的ASO表现出长时间的基因沉默效应.
- 与2'-MOE修饰的ASO相比,SNA修饰的ASO在和肝脏中显示出更有利的安全性概况.
结论:
- 经SNA修改的ASO代表了脏疾病的潜在下一代治疗平台.
- 这种方法结合了强大的基因沉默和提高耐受性,解决了当前ASO疗法的关键局限性.
相关概念视频
siRNA - Small Interfering RNAs
16.5K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.5K
Antihypertensive Drugs: Direct Renin Inhibitors
468
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
468
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
363
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
363
Renal Drug Excretion: Tubular Secretion
104
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
104
Experimental RNAi
6.0K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.0K
RNA Interference
25.9K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
25.9K


